How is 3B-NEO different from the existing Newborn Screening (NBS)?

Conventional newborn screening (NBS) aims to detect metabolic abnormalities or urgent conditions that are already manifested by measuring metabolites in the blood shortly after birth. However, the range of detectable conditions is limited, and because the underlying genetic causes are not directly analyzed, diagnostic blind spots may still exist.

3B-NEO is a genomic-based screening test that complements conventional NBS. Through whole-exome/genome sequencing (WES/WGS), it analyzes genetic risks that cannot be identified through biochemical testing alone, enabling broader detection of diverse actionable conditions in infants.

In addition, 3B-NEO goes beyond simply identifying the presence of genetic variants by providing clinical insights into the need for future precision monitoring and medical management. Furthermore, if the child later develops unexplained symptoms, the previously obtained genomic data can serve as a foundation for additional diagnostic approaches. In this respect, 3B-NEO is not merely a one-time test, but a potential starting point for lifelong precision medicine beginning in early life.

How is 3B-NEO different from the existing Newborn Screening (NBS)?

코멘트

답글 남기기 응답 취소